Table 2.
Selection of currently ongoing clinical trials evaluating CTLA4 or/and PD1/PD-L1 checkpoint blockade in combination with targeted therapy approaches for pancreatic cancer as indicated.
| Combination strategy/target | Compounds | Entity | Phase | Trial ID |
|---|---|---|---|---|
| Oncogenic signaling | Cobimetinib (MEK-inh.) + atezolizumab (PD-L1-Ab) | Metastatic PDAC, progressed on chemotherapy | Ib/II | NCT03193190 |
| TME: stroma | Ulocuplumab (CXCR-4-ant.) + nivolumab (PD-1-Ab) | Advanced/metastatic pancreatic cancer (next to SCLC) | I/II | NCT02472977 (terminated 03/2018 due to lack of effic. in short-term ph.) |
| BL-8040 (CXCR4-ant.) + pembrolizumab (PD-1-Ab) | (Pretreated) metastatic pancreatic cancer | II | NCT02826486 and NCT02907099 | |
| BL-8040 (CXCR4-ant.) + atezolizumab (PD-L1-Ab) | Metastatic PDAC, progressed on chemotherapy | Ib/II | NCT03193190 | |
| Olaptesed pegol (pegylated oligoribonucleotide, neutralizing CXCL12) ± pembrolizumab (PD-1-Ab) | Metastatic pancreatic cancer (next to CRC) | I/II | NCT03168139 | |
| Defactinib (FAK-inh.) + pembrolizumab (PD-1-Ab) | Advanced pancreatic cancer (next to NSCLC and mesothelioma) | I/II | NCT02758587 | |
| PEGPH20 (pegylated recombinant human hyaluronidase) + atezolizumab (PD-L1-Ab) | Metastatic PDAC, progressed on chemotherapy | I/II | NCT03193190 | |
| PEGPH20 (see above) + avelumab (PD-L1-Ab) | Chemotherapy resistant advanced pancreatic cancer | I | NCT03481920 | |
| Pembrolizumab (PD-1-Ab) ± paricalcitol (vitamin D analog) | Maintenance of pretreated advanced pancreatic cancer in (partial) remission | II | NCT03331562 | |
| TME: myeloid | RO7009789 (CD40 ago. Ab) + atezolizumab (PD-L1-Ab) | Locally advanced/metastatic solid tumors | I | NCT02304393 |
| Cabiralizumab (CSF1R-Ab) + nivolumab (PD-1-Ab) | Advanced solid tumors | I | NCT02526017 | |
| AMG820 (CSF1R-Ab) + pembrolizumab (PD-1-Ab) | Advanced pancreatic cancer (next to CRC and NSCLC) | I/II | NCT02713529 | |
| Pedixartinib (CSF1R-tyrosine kinase inh.) + durvalumab (PD-L1-Ab) | Pretreated advanced/metastatic pancreatic cancer (next to CRC) | I | NCT02777710 | |
| Acalabrutinib (bruton tyrosine kinase inh.) + pembrolizumab (PD-1-Ab) | Metastatic pancreatic cancer | II | NCT02362048 | |
| TME: metabolism | Epacadostat (IDO1-inh.) + pembrolizumab (PD-1-Ab) | Previously treated advanced pancreatic cancer (with chromosomal instability/HRRD) | II-withdrawn | NCT03432676 |
Ab, antibody; inh., inhibitor; ant., antagonist; ago., agonist; CRC, colorectal cancer; HRRD, homologous recombination repair deficiency; IDO1, indoleamine 2,3-dioxygenase 1; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; TME, tumor microenvironment; PD-1, programmed cell death protein 1.